March 1 (Reuters) - Gilead Sciences

* U.S. Food And Drug Administration Approves Gilead's Second Taf-Based single tablet regimen odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) for the treatment of HIV-1 infection

ADVERTISEMENT

* U.S. Food and drug administration approves Gilead's second taf-based single tablet regimen Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) for the treatment of HIV-1 infection

* Odefsey has a boxed warning in its product label regarding risks of lactic acidosis/severe hepatomegaly with steatosis

ADVERTISEMENT

* Odefsey has a boxed warning in its product label regarding risks of post treatment acute exacerbation of Hepatitis B Source text for Eikon: Further company coverage: